We identified four new isoforms of human CRH-R1 (e-h) and three of mouse (mCRH-R1c, e, and f). In all new forms exon 6 was missing. Human CRH-R1e was characterized by the deletion of exons 3 and 4; exon 12 from CRH-R1f; exon 11, 27 base pairs (bp) of exon 10 and 28 bp of exon 12 from CRH-R1g and CRH-R1h by the addition of a cryptic exon. In mouse CRH-R1c exon 3 was spliced out; in mCRH-R1e exons 3 and 4 and in mCRH-R1f exon 11 were spliced from mRNA. CRH-R1 was expressed in all skin specimens in patterns dependent on the cell type, physiological status, and presence of pathology. CRH-R1α, the most prevalent form, was detected in almost all samples. Ultraviolet radiation (UV) changed the splicing pattern and induced or increased expression of CRH-R1α in cultured skin cells. Continuing UV treatment of succeeding generations of cells resulted in a progressive increase in the number of CRH-R1 isoforms, which suggests that receptor heterogeneity might favor cell survival. TPA (phorbol 12-myristate 13-acetate), forskolin, dbcAMP (N6, 2'-O-dibutyryladenosine 3':5'-cyclic monophospate sodium), and IBMX (3-isobutyl-1-methylxanthine) also changed the splicing pattern. We suggest that a polymorphism of CRH-R1 expression is related to anatomic location, skin physiological or pathologic status, specific cell type, and external stress (UV), and that cAMP-dependent pathways and TPA may regulate CRH-R1.
C orticotropin releasing hormone (CRH), the most proximal element of the hypothalamicpituitary-adrenal (HPA) axis, coordinates the complex array of behavioral, autonomic, endocrine, and immune responses to stress. The peptide signal is translated into phenotypic effect through interaction with G-protein-coupled membrane-bound CRH receptors (1) . So far two subtypes of receptors (CRH-R1 and CRH-R2) have been characterized in human (2, 3) , rat (4, 5, 6) , mouse (7, 8, 9) , and Xenopus (10) . Most recently, a third subtype (CRH-R3) has been identified in catfish (11) .
CRH-R1 is a protein with 98% sequence homology among different mammalian species and ~30% homology with receptors for the gut-brain family of neuropeptides (1, 12, 13) . Human CRH-R1 gene contains 14 exons (14) . Four alternatively spliced CRH-R1 transcripts have been identified in humans. These are CRH-R1α, in which exon 6 is spliced out, generating a 13-exon transcript that produces a 415 amino acid (aa) protein (2); CRH-R1β, which contains all 14 exons, producing a 444 aa protein (2); a CRH-R1c isoform, in which exons 3 and 6 are spliced out to generate a 12-exon transcript producing a 375 aa protein (15) ; and a CRH-R1d isoform in which exons 6 and 13 are missing, which translates into a 401 aa protein (16) . CRH-R1 isoforms have different affinity to ligands and coupling to cAMP production. The major ligand-binding determinant of mammalian CRH-R1 has been mapped to its first extracellular domain (17) . This domain is coded by exons 1-4 of CRH-R1. The exon 3 contains two regions that are critical for high-affinity ligand binding, and mutations in this region abolish CRH binding (18) . Thus, CRH-R1c lacking exon 3 should have a decreased CRH binding capacity. A 29 aa insert corresponding to exon 6 of CRH-R1β has also been reported to decrease binding affinity as well as coupling of the receptor to G proteins (19) . CRH-R1d isoform lacking exon 13 has been cloned recently from human myometrium (16) . This isoform is poorly coupled to G proteins. Thus, it appears that CRH-R1α is the most efficient receptor isoform transducing CRH signal into cAMP-mediated pathways, whereas other isoforms either have a poor ligand binding capacity or are poorly coupled to cAMP production. Because a spectrum of receptor isoforms expressed by a cell can determine its response to the ligand, full molecular characterization of CRH-R1 transcripts is necessary to understand a pleiotropic role of CRH.
Skin, the largest body organ, maintains internal homeostasis by serving as a barrier between the external environment and the internal milieu. Being continuously exposed to noxious stimuli of varying intensity, including solar radiation, thermal energy, and biological agents, it requires a highly localized and precise mechanism for dealing with the immediacy of these interactions (20, 21) . Drawing an analogy to the central response to stress centered on the HPA axis, we have proposed that similar mediators could activate peripheral response to stress with a CRH-based signaling system playing a major regulatory role (22, 23, 24) . Both CRH and urocortin are produced in human and rodent human skin, accompanied by the expression of functional CRH-R1 (21-23, 25, 26) . We have proposed that the flow of information involving cutaneous CRH peptides could be arranged either hierarchically, from CRH through CRH-R1, activation of proopiomelanocortin (POMC) peptide production, and corresponding activation of the respective receptors for these peptides (22, 24) or directly through CRH-R1 activated pathways, regulating epidermal integrity, its barrier function, immunomodulation, dermal vascular function, and hair growth and pigmentation (20, 22, 24) . Such functional diversity may require specific molecular mediators. Functional selectivity could be achieved though differential expression of CRH-R1 isoforms. In the present study we examined the expression of CRH-R1 isoforms in various human and mouse skin samples and cell lines having different physiological and pathologic status and exposure to UV radiation. The observed expression patterns were compared with pituitary, brain, adrenals, and spleen CRH receptors.
MATERIALS AND METHODS

Tissues
Human tissue samples included specimens of pituitary, adrenal gland, and nonlesional (normal; five specimens) and pathologic (containing basal cell carcinoma; three specimens) skin. Skin and adrenal gland specimens were obtained from tissue removed during surgery; pituitaries were obtained from the National Hormone and Pituitary Program National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (Baltimore, MD). The tissues were stored at -80ûC until they were analyzed. The University of Tennessee Health Science Center (UTHSC) Committee on Research Involving Human Subjects approved the use of human tissues.
Murine samples consisted of brain, pituitary, spleen, and skin isolated at telogen and anagen IV, V, and VI stages of hair cycle. Mice C57BL/6 strain female (8 weeks old) were purchased from Taconic Farms (Taconic, NY) and housed in community cages at the animal facilities of the Albany Medical College (AMC; Albany, NY). The animals were killed under pentobarbital anesthesia, and selected organs as well as back skin were collected following protocols routinely used in our laboratory (23, 27) . Tissue specimens were frozen rapidly in liquid nitrogen and stored at -80ûC until further analysis. The Institutional Animal Care and Use Committee at AMC originally approved the experimental protocol, and a similar protocol for mice was approved at UTHSC. The tissues were pulverized in liquid nitrogen with the help of mortar and were then suspended in Trizol (Gibco-BRL, Gaithersburg, MD). The isolation of RNA followed the manufacturer protocol.
Cell culture
Cell lines were cultured according to standard protocols as described previously, and media were changed every second day (28, 29) . CO 2 concentration was 5% with exception of mouse normal melanocytes (see below). Human immortalized keratinocytes (HaCaT) and squamous cell carcinoma (C 4-1 ), were propagated in Dulbecco's modified Eagle's medium (DMEM) medium (GIBCO), while human melanoma (SKMEL188) and mouse Cloudman S91 melanoma (sublines #6 and M3) cells were grown in Ham's F10 medium (FBS) as described previously. The media were supplemented with 10% FBS and antibiotics (GIBCO) (28, 29) . Additional human melanoma cells included those established from radial growth phase (WM 35 and SBCE2), vertical growth phase (WM 98 and WM 1341D), and metastatic (WM 164) melanomas (gift of M. Herlyn, Wistar Institute, Philadelphia, PA). They were cultured in DMEM supplemented with 10% FBS, insulin (5 µg/ml) and antibiotics.
Immortalized normal mouse skin melanocyte line MelA (gift of D. Bennett, Saint George Hospital London, England) was cultured in RPMI 1640 media supplemented with 10% of bovine serum and 200 nM TPA (phorbol 12-myristate 13-acetate) in the presence of 10% CO 2 . Normal human neonatal keratinocytes from passages 2 and 3 were used for experiments (25) . Primary cell cultures were established from foreskin as described previously (25) . The cells were propagated in low-calcium (0.15 mM) serum-free Keratinocyte Growth Medium containing bovine pituitary extract and antibiotics (Clonetics Corp., San Diego, CA). Normal human neonatal melanocytes were cultured in medium 154 (Cascade Biologicals, Portland, OR) supplemented with 5% FBS, 13 µg/ml bovine pituitary extract (BPE), and 8 nM TPA, 1 µg/ml α-tocopherol, 0.6 ng/ml basic fibroblast growth factor, 1 µg/ml transferrin, and 5 µg/ml insulin (all from Sigma) (30) . After being washed with phosphate buffered saline (PBS), melanoma cells were detached with Tyrode's solution containing 1 mM ethylenedinitrilo-tetraacetic acid, disodium salt, dihydrate (28) ; keratinocytes and normal melanocytes were trypsinized (26, 29) . The cells were centrifuged and suspended in RNA isolation solution (Trizol reagent).
In some experiments SKMEL188, HaCaT, and C 4-1 cells were also treated with TPA, forskolin, or a mixture of IBMX (3-isobutyl-1-methylxanthine) and dbcAMP (N6, 2'-O-dibutyryladenosine 3':5'-cyclic monophospate sodium) (all from Sigma). Briefly, the cells were transferred to 75 cm 2 flasks ( 
Irradiation of cell lines by UV
SKMEL188, HaCaT, and C 4-1 cells were exposed to UV radiation produced by UV transilluminator 2000 (BioRad). Cells were transferred to 9 cm Petri dishes at a concentration of 10 6 cells/dish and were grown for 24 h in standard conditions described above. Before irradiation, medium was aspirated and substituted by 10 ml of PBS. The dishes were placed on the UV transilluminator and incubated for 3, 12, and 31 s corresponding to 5, 20, and 50 mJ/cm 2 doses of UVB, respectively. Time of exposure and corresponding doses were calculated by the standard formula:
The spectrum of UV irradiation of the transilluminator 2000 was measured by using Optronic spectroradiometer, model 754 (Fig. 1) After irradiation, PBS was substituted by standard culture medium. Cells were incubated for 24 h, detached, collected by centrifugation, and dissolved in RNA isolation solution (Trizol reagent). Alternatively, cells were cultured in standard medium for 2 weeks until their full recovery. At this point cells were collected for RNA isolation or irradiated by additional UV dose (50 mJ/cm 2 of UVB). The irradiated cells were incubated for two weeks in standard medium until full recovery and then irradiated again. The UV irradiation process was repeated three times.
RNA extraction and cDNA preparation
We extracted total RNA by using the Trizol isolation kit (Gibco-BRL, Gaithersburg, MD). The synthesis of first-strand cDNA was performed by using the Superscript preamplification system (Gibco-BRL). We reverse-transcribed 5 µg of total RNA per reaction by using oligo(dT) as the primer.
Polymerase chain reaction
We used nested polymerase chain reaction (PCR) to detect different CRH-R1 isoforms. We conducted the first round of amplification of human CRH-R1 fragment spanning exons 2-7 by using 2 µl of cDNA and primers: P110, 5'-TCCGTCTCGTCAAGGCCCTTC-3' (sense), and P111, 5'-GGCTCATGGTTAGCTGGACCAC-3' (antisense). We transferred aliquots of PCR mixture from the first round of amplification to a new tube and conducted a second round of PCR. Primers for the second round of PCR were P112, 5'-TGTCCCTGGCCAGCAACATCTC-3' (sense), and P113, 5'-AGTGGATGATGTTTCGCAGGCAC-3' (antisense). Amplification of exons 9 through 14 of human CRH-R1 was done in the same way. Primers for the first round of PCR: P114, 5'-CCATTGGGAAGCTGTACTACGAC-3' (sense), and P115, 5'-GCTTGATGCTGTGAAAGCTGACAC-3' (antisense). Primers for the second round of PCR: P116, 5'-GGGTGTACACCGACTACATCTAC-3' (sense), and P117, 5'TCTTCCGGATGGCAGAACGGAC-3' (antisense). Primers for the first round of amplification of mouse CRH-R1 fragment spanning exons 2-6: P156, 5'-TCCGGCTCGTGAAGGCCCTTC-3' (sense), and P157, 5'-GCTCAGGGTGAGCTGGACCAC-3' (antisense). Primers for the second round of PCR: P158, 5'-TGTCCCTGGCCAGCAATGTCTC-3' (sense), and P159, 5'-AGTGGATGATGTTCCTCAGGCAC-3' (antisense). Primers for the first round of amplification of mouse CRH-R1 fragment spanning exons 8-13: P160, 5'-CCATTGGGAAACTTTACTACGAC-3' (sense), and P161, 5'-CTTGATGCTGTGGAAGCTGACTC-3' (antisense). Primers for the second round of PCR: P162, 5'-AAAAGTGCTGGTTTGGCAAACGTC-3' (sense), and P163, 5'-CTTCCGGATGGCAGAGCGGAC-3' (antisense).
All samples were standardized for the analysis by the amplification of housekeeping gene glyceraldehyde phosphate dehydrogenase (GAPDH). Primers for the GAPDH gene were as described by Robbins and Mc Kinney (31) . GAPDH gene expression was tested in all samples to ensure the integrity of isolated RNA. GAPDH amplification products were separated by agarose electrophoresis and were visualized by ethidium bromide staining according to standard protocol used in our laboratory (23) .
Sequencing
The identified PCR products were excised from the agarose gel and purified by GFX PCR DNA and gel band purification kit (Amersham-Pharmacia-Biotech). PCR products were sequenced from both ends. We performed sequencing in the Molecular Resource Center at the University of Tennessee HSC (Memphis) by using Applied Biosystems 3100 Genetic Analyzer and BigDye™ Terminator Kit. The sequence data have been submitted to GeneBank database under accession numbers AF369651, AF369652, AF369653, AF374231, AF369654, AF369655, and AF369656.
RESULTS
Human
Alternative splicing of human CRH-R1
Two sets of nested primers were designed to amplify the regions of human CRH-R1 mRNA spanning exons 2 through 7 and 9 through 14 (Fig. 2) . These regions contain exons 3, 6, and 13, which are more likely to be spliced out from human CRH-R1 mRNA. CRH-R1 mRNA expression was detected in all human tissues and cell lines tested, including pituitary, adrenal gland, skin, normal neonatal melanocytes, and keratinocytes, immortalized HaCaT keratinocytes, squamous cell carcinoma C 4-1 , and melanoma cell lines ( Fig. 3A and 4A ). The visualized amplification products were cut from the gels and were sequenced. The characteristics of detected isoforms are presented in Table 1 . In addition to previously described CRH-R1α, c, and d, we identified and named four new isoforms: CRH-R1e (AF369651), CRH-R1f (AF369652), CRH-R1g (AF369653), and CRH-R1h (AF374231). The splicing pattern is presented in Fig. 2 and Table 1 . All of these isoforms have exon 6 spliced out from the final transcript. Furthermore, in CRH-R1e exons 3 and 4 are spliced out ( Table 1 ). CRH-R1h contains insertion of cryptic exon (110 bp) between exons 4 and 5 (Fig. 4B, Table 1 ).
Predicted protein sequences of these new isoforms in comparison with the CRH-R1 variants α, β, c, and d are presented in Figure 5 . CRH-R1e and CRH-R1f have frame shifts (Fig. 2) . CRH-R1e mRNA has two potential reading frames one of 585 bp and the second of 723 bp (Figs. 2, 5 ). The first one encodes 194 aa protein (CRH-R1e1) containing only first 40 aa from N-terminus encoded by exons 1 and 2; the remaining (Fig. 5 , CRH-R1e1, underlined) amino acids sequence differs from that encoded by other isoforms and does not contain transmembrane binding domains (Figs. 2, 5 ). The second reading frame can potentially code a membrane-bound protein of 240 aa (CRH-R1e2) with a sequence starting from the third transmembrane domain and containing C terminus (Fig. 5) . Reading frame for CRH-R1f is 1113 bp long and encodes a receptor protein of 370 aa containing entire CRH-binding domain and first five transmembrane domains (215 aa); the remaining C terminal sequence (underlined) differs from other forms due to frame shift (Fig. 5) . The most unusual isoform was CRH-R1g, which has preserved the reading frame of CRH receptor. It encodes a membrane-bound protein of 341 aa that has a deletion of 74 amino acids, corresponding to transmembrane domains 5 and 6 (Fig. 5) . The insertion of a 110-bp-long cryptic exon between exons 4 in CRH-R1h isoform would generate truncated protein of 145 aa with only CRH-binding domain (coded by exons 1-4), because the inserted exon contains translation terminator (AF374231). Here, we should emphasize that the functions of each protein are predictions only and that their further characterization would require functional assays.
The expression pattern of CRH-R1 isoforms in tested tissues and cell lines is summarized in Table 2 . CRH-R1α was the most widely expressed isoform (369 bp fragment in Fig. 3A ; 336 bp in Fig. 4A) ; it is detectable in pituitary, adrenal gland, and in all cell lines, as well as in skin samples with the exception of one skin biopsy containing basal cell carcinoma. CRH-R1c isoform was expressed only in the skin containing basal cell carcinoma (Fig. 3A, lanes 7 and 8,  249 bp fragment) . CRH-R1d isoform was detected in the pituitary, neonatal normal keratinocytes and in five melanoma lines (294 bp fragment; Fig. 4A , lanes 2 and 5, Table 2 ). CRH-R1e was detected in skin containing basal cell carcinoma and in four melanoma lines (Table 2 ). CRH-R1f was detected in one skin biopsy with basal cell carcinoma, in normal neonatal keratinocytes, squamous cell carcinoma line, and three melanoma lines ( Table 2 ). The most widely distributed among newly characterized isoforms was CRH-R1g that was detected in pituitary, adrenals, normal and pathologic skin, neonatal keratinocytes, and five melanoma lines ( Table 2 ). The only isoform that we could not detect in the tested samples was CRH-R1β.
Environmental regulation of CRH-R1 splicing
To test the hypothesis that environmental stress can change cutaneous expression of CRH-R1, we exposed human HaCaT immortalized keratinocytes, SKMEL188 melanoma, and C 4-1 squamous cell carcinoma cells to UV radiation. Ultraviolet irradiation changed significantly the spectrum of CRH-R1 isoforms detected (Figs. 3 and 4 and Table 3 ). In SKMEL188 UV switched the expression from CRH-R1d isoform to CRH-R1α and CRH-R1g (Fig. 4D, Table 3 ). In HaCaT keratinocytes, first exposure to UV increased only expression of CRH-R1α without changing the isoforms pattern (compare lanes 2 and 6 on Fig. 4B, Table 3 ). In C 4-1 cells, UV inhibited expression of CRH-R1f and induced the expression of CRH-R1g (Fig. 4C, lanes 1 and 5, Table  3 ). Because ~50% of cells exposed to UV die within 3 days after treatment, we also investigated the cells that survived such treatment to establish whether a new pattern of CRH-R1 splicing is maintained in the succeeding generations. Such a pattern could represent a factor affecting the survival of cells in the stressful conditions. To study these questions, we investigated the CRH-R1 splicing pattern in cells that started rapid growth 2-3 weeks after the irradiation (UV plus incubation, Table 3 ). Alternatively, we irradiated these cultures by a new dose of UV and again incubated them for 2-3 weeks at standard conditions. We found out that the CRH-R1 splicing did not return to the original pattern (Table 3 , Fig. 3B-D, Fig. 4B-D) . Thus, cultured human melanoma preserved UV-induced CRH-R1α and CRH-R1g expression (Fig. 4D, Table 3 ). However, expression of CRH-R1α isoform increased in cells cultured for 2 weeks after incubation after irradiation (compare lanes 2 and 6 on Fig. 3D or lanes 2 and 7 on Fig. 4D ). HaCaT keratinocytes gained CRH-R1c and g isoforms after second UV treatment and CRH-R1e after third UV treatment (Fig. 3B and 4B , Table 2 ). C 4-1 cells cultured for 2 weeks after second UV treatments expressed CRH-R1c, e, and g isoforms in addition to the CRH-R1α (Fig. 3C, lane  8 ; Fig. 4C, lane 7) . Thus, repeated treatment of the epithelial cells (HaCaT and C 1-4 cells) by UV increased the number of CRH-R1 isoforms expressed (Table 3) .
To test whether cAMP-dependent and TPA-induced pathways can change CRH receptor expression, we incubated cell lines in the presence of TPA, forskolin, or a mixture of IBMX and dbcAMP. We observed the differential and cell-specific splicing pattern. In human melanoma cells, TPA shifted CRH-R1 splicing from CRH-R1d to CRH-R1α isoform (Fig. 4D, Table 3 ). Forskolin or dbcAMP plus IBMX inhibited expression of CRH-R1d and stimulated expression of CRH-R1α and g isoforms; the pattern was identical to that induced by the UV (Table 3, Fig. 4D ). In C 4-1 cell line all of these compounds switched off CRH-R1f isoform expression and induced CRH-R1g; the pattern was again identical to that induced by UV (Table 3, Fig. 4C ). In HaCaT keratinocytes TPA induced an insertion of 110 bp fragment between exons 4 and 5 of CRH-R1 (Fig. 3B lane 3, 479 bp fragment) , which lead to a premature translation termination due to the presence of termination codon in the inserted sequence. We named this isoform CRH-R1h (Table  1) . In these cells forskolin had no effect on splicing, whereas dbcAMP plus IBMX induced expression of CRH-R1e and g forms (Table 3 ). To recapitulate forskolin and dbcAMP plus IBMX but not TPA-stimulated CRH-Rg isoform expression in all cell lines tested (with exception of HaCaT cells in case of forskolin) (Table 3 ), and also increased the level of CRH-R1α expression (compare lanes 2-5 in Fig. 3C, Fig. 4B, or Fig. 4D ).
Mouse
Splicing of CRH-R1 in mouse
So far, only one CRH-R1 isoform was described in mice; for example, an analog of human CRH-R1α (7). To test CRH-R1 expression pattern in mouse we screened different mouse tissue samples (Table 2 ) with a set of specific primers of which exonal location is listed in Fig. 2 . The exonal allocation is based on rodent (rat) gene structure that is similar to that in humans except that it does not contain exon 6 (14, 32). The detected isoforms have been marked with letter "m" to emphasize the murine origin as counterpart of the human receptor form. Amplification of mouse cDNA showed that mRNA of mCRH-R1α was expressed in mouse brain; pituitary; spleen; mouse anagen IV, V, and VI skin; normal melanocytes; and Cloudman S91 melanoma cells ( Fig. 6 and Table 2 ). The α isoform was absent in resting (telogen) skin. In addition to mCRH-R1α three new isoforms were detected (Fig. 2, Table 1 ). One of them is analogous to human CRH-R1c isoform (AF369654), lacking part of CRH-binding domain due to the absence of exon 3 (Table 1 ). This encodes a protein of 375 aa, and by analogy with human counterpart (17, 18, 33) would have a decreased affinity to CRH. It is expressed only in anagen (IV-VI) skin and spleen (Fig. 6 and Table 2 ). The other two are homologues of human CRH-R1e and CRHR1f. Those two also have deletions of exons 3 plus 4 (AF369655) and 11 (AF369656), respectively; leading to frame shifts and consequently changes in amino acid sequences of the receptor protein (Fig. 5) . Mouse CRH-R1e mRNA also has two potential reading frames: one of 420 bp and a second of 930 bp (Fig. 5) . The first one encodes protein (CRH-R1e1) of 139 aa that similarly to the human counterpart contains only first 40 aa from the N-terminus of the CRH-R1 without transmembrane domains due to the frame shift (Fig. 5, underlined) . The second frame potentially can encode a membrane-bound protein of 309 aa (mCRH-R1e2) with a sequence starting from the first transmembrane domain and containing C terminus (Fig. 5) . Reading frame for CRH-R1f (990 bp) encodes a receptor protein of 329 aa containing an entire CRH-binding domain, seven transmembrane domains, and a proximal part of C terminus; the distal part of C terminus is missing due to absence of exon 12 (Figs. 2 and 6 ). mCRH-R1e is expressed in brain, pituitary, telogen and anagen skin, whereas mCRH-R1f is expressed in anagen skin and M3 subline of Cloudman S91 melanoma (Table 2) .
DISCUSSION
So far, four isoforms of the human CRH receptor type 1 have been described: CRH-R1α (lacking exon 6), CRH-R1β (containing all 14 exons), CRH-R1c (lacking exons 3 and 6), and CRH-R1d (lacking exons 6 and 13). In the mouse, only one isoform, equivalent to human CRH-R1α, has been characterized (7) . In the present study we found four new types of human CRH-R1 mRNA: CRH-R1e, f, g, and h, and three new mouse isoforms homologous to human CRH-R1c, e, and f. In humans, in addition to exon 6, exon 12 was spliced from CRH-R1f, exons 3 and 4 were spliced from CRH-R1e, exon 11, and 27 bp of exon 10 and 28 bp of exon 12 from CRH-R1g. CRH-R1h had a cryptic exon; that is, an insertion of 110-bp-long sequence between exons 4 and 5 (Fig. 2) . The mouse sequence does not contain exon 6, and, in a sequence similar to humans, exon 3 is spliced-out in mCRH-R1c and exons 3 and 4 in mCRH-R1e, whereas exon 11 is missing in mCRH-R1f (Fig. 2) . Alternative splicing is a tightly regulated process, generating different mRNAs and increasing the coding capacity of genes (34) (35) (36) . Approximately 33%-59% of human genes have at least two variants (37). For example, 576 possible alternative forms of a K+ channel are expressed in a gradient along the 10,000 sensory-receptor cells present in the inner ear of birds, enabling perception of different sound frequencies (38) . Furthermore, 15% of the point mutations that cause diseases in humans alter the normal splicing pattern (36, 39) . Thus, the described spectrum of CRH-R1 isoforms in human and mouse may reflect the diverse phenotypic functions of CRH and related peptides, requiring precise and selective coupling of signal transduction pathways.
Some information on the potential role(s) of new isoforms in phenotypic regulation can be obtained from the analysis of predicted structure of protein products and the gene expression pattern in different cellular compartments (Fig. 5, Table 2 ). Thus, human and mouse CRH-R1e isoforms contain two reading frames, of which one encodes soluble proteins of 194 aa in human and of 139 aa in mouse containing first 40 aa of distal N-terminal sequence with a remaining sequence different from the CRH-R1 receptor due to the frame shift. Because of lack of exons 3, 4, and transmembrane domains, it should not act as a CRH binding protein (17, 18, 33) . The second form (human, 240 aa; mouse, 309 aa) with a sequence starting from the third transmembrane domain in human and first transmembrane domain in mouse contains C terminus (Fig. 5 ). It will not be able to bind a ligand because of lack of N terminus. Similarly, the newest CRH-R2 isoform detected in the stomach also consists of only the C-terminal part of the CRH-R2 (GeneBank accession No. E12750; [40] ). Human CRH-R1f encodes entire CRH-binding domain and the first five transmembrane domains and, therefore, it should bind CRH and fix it on the outer surface of cellular membrane. Thus, it may decrease local concentration of CRH or serve as a pool of bound hormone. The murine form of this receptor also encodes entire Nterminus and five transmembrane domains. The type of signal transduction pathway to which it is coupled remains to be investigated. The most unusual isoform we detected was CRH-R1g in which the reading frame was preserved, but the protein sequence had a deletion of 74 amino acids, corresponding to transmembrane domains 5 and 6. This kind of receptor can be potentially coupled to the production of cAMP. Finally, CRH-R1h isoform encodes truncated protein having only CRH-binding domain (coded by exons 1-4), because the cryptic exon 4 contains translation terminator (Fig. 5) . It can potentially interfere with the binding of CRH or serve as an analog of CRH binding protein. Of note, tested mouse tissues did not express CRH-R1g and h forms, emphasizing interspecies differences.
Among already described isoforms, CRH-R1α is the most efficient receptor variant, which transduces peptide signals into cAMP-mediated pathways, whereas other forms (β, c, d) either have a decreased ligand binding capacity (β, c) or are poorly coupled to cAMP production (β, d) (16, 18, 19) . CRH-R1α was the most prevalent form detected in almost all samples tested, with the exception of one human melanoma cell line (SKMEL188), one skin biopsy containing basal cell carcinoma, and the mouse telogen skin. The dominant role of CRH-R1α in the skin is emphasized further by the induction or expression stimulation (in human melanoma and keratinocytes) by UV and factors raising cAMP. There was also hair-cycle-dependent expression in murine skin (present in anagen and absent in telogen). Of note, pigmentary, metabolic, endocrine, and immune activities of mouse skin fluctuate along hair cycle, which is low in telogen (resting phase) and high in anagen (growing phase of hair cycle) (20, 21, 41) . The second most frequent form detected in human tissues was CRH-R1g, which can be potentially coupled to the cAMP production. We suggest therefore that the main pathway activated by CRH (or related peptides) in the skin involves increased production of cAMP. Establishing a role of other isoforms in cutaneous signaling would require additional experimental testing that is beyond the scope of this study.
CRH-R1β was not detected in samples deriving from human corporal skin, which suggests lack of expression in the tested material. This finding agrees with our previous study showing absence of CRH-R1β in corporal skin and cultured melanocytes and keratinocytes, and its restricted expression to the scalp (24) . Alternatively, the negative results may be due to the preferential amplification of the shorter PCR fragments. However, most of PCR reactions produced several bands of different length, which implies that one isoform did not completely dominate the amplification reaction. Alfa isoform, which is only 87 bp shorter, was detected in almost all tested samples. Thus, even if the CRH-R1β isoform is present in the corporal skin, the level of its expression is below delectability by our method of detection.
Given that CRH signaling plays a central role in response to stress (20) (21) (22) , it would be expected that environmental stressors would act, changing the expression pattern of CRH-R1 to counteract damaging effects of external or internal insults. The experiments with the UV irradiation that changed the pattern of receptor splicing in tested skin-derived cell lines support this concept. Thus, CRH-R1 mRNA splicing was changed from d to α and g isoforms in human melanoma cell line; CRH-R1α and g also increased in UV treated normal (immortalized) and malignant keratinocytes. Again, this pattern suggests that cutaneous stress stimulates the expression of isoforms that are or can be coupled to cAMP production. It is also significant that the newly gained pattern of CRH-R1 splicing appears to be stable; for example, it does not regress even after prolonged cultivation (more that 2 weeks in culture). Although it is unclear how this splicing is preserved, we suggest that this new pattern somehow promotes survival of cells damaged by UV radiation. Repeated treatments by UV led to an increase of CRH-R1 isoforms expressed in normal and malignant keratinocyte lines, with the resulting populations expressing CRH-R1c, e, f, and g isoforms in addition to initial CRH-R1α. Thus, it appears that repeated stress favors the survival of cells having a diverse spectrum of CRH receptor isoforms, probably reflecting induced cellular heterogeneity of these lines. By analogy with tumor biology (42) , such heterogeneity could play a role in stabilizing phenotype of the cell line making it resistant to external manipulation. Pawelek et al. (43, 44) proposed that melanocyte response to solar radiation is highly regulated, involving UV-stimulated expression, activation of MSH receptors, and increased production of their ligands; for example, POMC-derived MSH and ACTH. We also note that UV induced CRH-R1 expression with preference for the most efficient α isoform and production of the respective CRH ligand (45) . Thus, this general molecular mechanism of UV action on epidermal cells (43, 44) may be conserved and would involve stimulation of CRH and POMC peptides production accompanied by induction and modification of the corresponding receptors (20, 45, 46) .
To better understand the mechanism of differential CRH-R1 splicing, we tested the effect of factors raising intracellular cAMP and of TPA. Factors raising intracellular cAMP increased CRH-R1 expression and switched the pattern to predominant expression of the α and g isoforms. This pattern was similar or identical to that induced by ultraviolet radiation, suggesting that similar mechanisms regulate CRH-R1 expression, being tightly linked to cAMP-activated signaling pathway(s). TPA also switched receptor splicing, however, the pattern or expression levels were different from those induced by UV or cAMP dependent signals. Thus, we suggest that cutaneous CRH-R1 gene expression can be regulated by at least two different signaling systems: one activated by UV and cAMP, and the second by TPA.
In summary, we found that CRH-R1 is spliced differentially in a variety of human and mouse tissues; we also identified the new isoforms of the receptors and noted a pattern of environmental regulation in cultured skin cells. In conclusion, we suggest that a polymorphism of CRH-R1 expression appears to be related to anatomic location, skin, physiological and pathologic status, and cell type; in addition external stress (UV), cAMP-dependent pathways, and TPA can also regulate CRH-R1 expression in skin cells. Table 1   Table 2   Table 3 Fig. 1 
